These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 23974470)

  • 1. Can the NICE "end-of-life premium" be given a coherent ethical justification?
    Cookson R
    J Health Polit Policy Law; 2013 Dec; 38(6):1129-48. PubMed ID: 23974470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of economic evaluations in NHS decision-making: a review and empirical investigation.
    Williams I; McIver S; Moore D; Bryan S
    Health Technol Assess; 2008 Apr; 12(7):iii, ix-x, 1-175. PubMed ID: 18373906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals.
    Bryan S; Williams I; McIver S
    Health Econ; 2007 Feb; 16(2):179-93. PubMed ID: 16960851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): no(t yet an) exemplar of a deliberative process.
    Schlander M
    J Med Ethics; 2008 Jul; 34(7):534-9. PubMed ID: 18591289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients' views of explicit rationing: what are the implications for health service decision-making?
    Devlin N; Appleby J; Parkin D
    J Health Serv Res Policy; 2003 Jul; 8(3):183-6. PubMed ID: 12869346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence and values: paying for end-of-life drugs in the British NHS.
    Chalkidou K
    Health Econ Policy Law; 2012 Oct; 7(4):393-409. PubMed ID: 23079299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NICE and Fair? Health Technology Assessment Policy Under the UK's National Institute for Health and Care Excellence, 1999-2018.
    Charlton V
    Health Care Anal; 2020 Sep; 28(3):193-227. PubMed ID: 31325000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales.
    Birch S; Gafni A
    Health Econ; 2002 Apr; 11(3):185-91. PubMed ID: 11921316
    [No Abstract]   [Full Text] [Related]  

  • 9. Public healthcare resource allocation and the Rule of Rescue.
    Cookson R; McCabe C; Tsuchiya A
    J Med Ethics; 2008 Jul; 34(7):540-4. PubMed ID: 18591290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating 'costs' for cost-effectiveness analysis.
    Miners A
    Pharmacoeconomics; 2008; 26(9):745-51. PubMed ID: 18767895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Justice, Transparency and the Guiding Principles of the UK's National Institute for Health and Care Excellence.
    Charlton V
    Health Care Anal; 2022 Jun; 30(2):115-145. PubMed ID: 34750743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NICE's selective application of differential discounting: ambiguous, inconsistent, and unjustified.
    O'Mahony JF; Paulden M
    Value Health; 2014 Jul; 17(5):493-6. PubMed ID: 25128041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does NICE apply the rule of rescue in its approach to highly specialised technologies?
    Charlton V
    J Med Ethics; 2022 Feb; 48(2):118-125. PubMed ID: 33685978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Saying no isn't NICE - the travails of Britain's National Institute for Health and Clinical Excellence.
    Steinbrook R
    N Engl J Med; 2008 Nov; 359(19):1977-81. PubMed ID: 18987366
    [No Abstract]   [Full Text] [Related]  

  • 16. Is the aim of the English health care system to maximize QALYs?
    Shah K; Praet C; Devlin N; Sussex J; Appleby J; Parkin D
    J Health Serv Res Policy; 2012 Jul; 17(3):157-63. PubMed ID: 22767891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The NHS: assessing new technologies, NICE and value for money.
    Stevens A; Chalkidou K; Littlejohns P
    Clin Med (Lond); 2011 Jun; 11(3):247-50. PubMed ID: 21902077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?
    Sculpher M; Palmer S
    Pharmacoeconomics; 2020 Mar; 38(3):247-257. PubMed ID: 31930460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Some inconsistencies in NICE's consideration of social values.
    Paulden M; O'Mahony JF; Culyer AJ; McCabe C
    Pharmacoeconomics; 2014 Nov; 32(11):1043-53. PubMed ID: 25145802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of NICE technology appraisal in NHS rationing.
    Walker S; Palmer S; Sculpher M
    Br Med Bull; 2007; 81-82():51-64. PubMed ID: 17409119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.